Wedbush Securities Inc. Boosts Holdings in Becton, Dickinson and Company $BDX

Wedbush Securities Inc. grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 53.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,473 shares of the medical instruments supplier’s stock after purchasing an additional 3,658 shares during the period. Wedbush Securities Inc.’s holdings in Becton, Dickinson and Company were worth $1,960,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BDX. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and Company by 15.4% in the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after purchasing an additional 4,305,947 shares during the last quarter. Norges Bank purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at $653,377,000. First Eagle Investment Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 59.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after acquiring an additional 3,268,478 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Becton, Dickinson and Company by 24.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after acquiring an additional 1,670,590 shares in the last quarter. Finally, Laurel Wealth Advisors LLC increased its stake in Becton, Dickinson and Company by 16,974.4% in the second quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock valued at $272,049,000 after acquiring an additional 1,570,136 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 2,463 shares of company stock valued at $501,530. 0.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent research reports. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday. JPMorgan Chase & Co. cut their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research note on Tuesday. Piper Sandler reiterated a “neutral” rating and issued a $170.00 target price (down previously from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday. Finally, Citigroup lowered their price target on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $195.46.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Jefferies initiated/issued a buy/recommendation on BDX, signaling conviction from at least one active analyst and supporting near-term demand for the shares. Becton Dickinson (BDX) Gets a Buy from Jefferies
• Positive Sentiment: TD Cowen raised its price target to $189 (from $183) and kept a hold rating — a modest positive reaffirmation that implies upside from current levels. TD Cowen adjusts Becton Dickinson PT to $189
• Positive Sentiment: BDX completed its Biosciences & Diagnostics spin-off and merged that unit with Waters, securing about $4B in proceeds and repositioning BDX as a pure‑play MedTech company — this materially improves balance-sheet flexibility and focuses growth strategy. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Company commentary and analysis (Q4 deep dive) indicate portfolio reshaping and targeted product investments have helped offset tariff headwinds — a constructive operational narrative for medium-term margins. BDX Q4 Deep Dive
• Neutral Sentiment: Citigroup revised its price target (reported as a lower target of $232) — still above current levels, so this is mixed: a cut in outlook from one bank but not a bearish absolute level. Citigroup Lowers BDX Price Target to $232
• Neutral Sentiment: Roundups and analyst-coverage pieces summarize a split street: several firms remain constructive while others are cautious, leaving consensus near-term guidance mixed. Are Wall Street Analysts Bullish on BDX?
• Negative Sentiment: Zacks Research downgraded BDX from Hold to Strong Sell — a sharp negative signal that can trigger selling by some momentum/quant funds and influences retail sentiment. Zacks downgrade
• Negative Sentiment: JPMorgan and Wells Fargo published pessimistic forecasts/comments on BDX, adding coordinated downside pressure from large institutional analysts. JPMorgan pessimistic forecast Wells Fargo pessimistic forecast
• Negative Sentiment: Market reports note shares gapped down on the analyst downgrade wave, reflecting immediate selling pressure following the negative analyst actions. BDX Shares Gap Down on Analyst Downgrade

Becton, Dickinson and Company Stock Down 1.5%

Shares of Becton, Dickinson and Company stock opened at $177.93 on Friday. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $185.02. The company has a market cap of $50.66 billion, a P/E ratio of 29.03, a PEG ratio of 2.38 and a beta of 0.25. The company’s fifty day simple moving average is $199.18 and its two-hundred day simple moving average is $192.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the prior year, the business earned $3.43 EPS. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.